title: [Prognostic significance of EBMT score for chronic myeloid leukemia patients in allogeneic stem cell transplantation].
abstract: OBJECTIVE
  To analyze the risk factors of allogeneic stem cell transplantation (allo-SCT) for chronic myeloid leukemia (CML) in an attempt to avoid transplant risks.
  
  
  METHODS
  A total of 121 CML patients received allo-SCT were analyzed retrospectively. The risk analysis was based on the EBMT score (gratwohl score) which included donor type, age of patients, disease status before transplantation, donor/recipient sex match and time interval between diagnosis to allo-SCT. Patients were divided into 3 risk groups based on their EBMT score: low risk (score 0-2), intermediate risk (3-4) and high-risk (5).
  
  
  RESULTS
  The median follow-up duration was 37 (1 - 126) months. The estimated 5-year overall survival (5 y-OS), non-relapse mortality (5 y-NRM) and relapse rate (5 y-RR) were (56.8 ± 5.0)%, (35.6 ± 4.9)% and (12.9 ± 3.7)%, respectively. The 5y-OS, NRM and RR were (66.0 ± 6.1)%, (28.8 ± 6.0)% and (7.8 ± 3.3)% in the low risk group being significantly superior to both intermediate-risk \[(47.2 ± 8.7)%, (43.6 ± 8.5)% and (18.7 ± 8.1)%\] and high-risk group \[(16.8 ± 15.2)%, (66.7 ± 25.5)% and (50.0 ± 25.0)%\] (P = 0.0015, 0.045 and 0.0053 for OS, NRM and RR respectively).
  
  
  CONCLUSIONS
  The EBMT risk score can effectively predict the overall outcome, relapse and transplant-related mortality of allo-SCT for CML patients.
authors.affiliation: Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
authors.forename: Jiong
authors.initials: J
authors.lastname: Hu
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Zhang
authors.forename: Dan
authors.initials: D
authors.lastname: Yang
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.forename: Xian-min
authors.initials: XM
authors.lastname: Song
authors.forename: Ling
authors.initials: L
authors.lastname: Wang
authors.forename: Wei-li
authors.initials: WL
authors.lastname: Zhao
authors.forename: Wen
authors.initials: W
authors.lastname: Wu
authors.forename: Jian-min
authors.initials: JM
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D055815:Young Adult